Volume 11, Number 9—September 2005
Research
Trypanosomiasis Control, Democratic Republic of Congo, 1993–2003
Pascal Lutumba*†, Jo Robays†, Constantin Miaka mia Bilenge*, Victor Kande Betu Ku Mesu*, Didier Molisho‡, Johan Declercq§, Wim Van der Veken§, Filip Meheus¶, Jean Jannin#, and Marleen Boelaert†
Table 4
Estimated costs of anti-HAT drugs consumed in the Democratic Republic of Congo from 2001 to 2003, based on observed number of patients treated by regimen*†
| Drug | Observed no. patients treated | Drug quantity/patient required | Total quantity drugs required | Unit price‡ US$ | Total (US$) |
|---|---|---|---|---|---|
| Pentamidine | 13,957 | 8 | 111,656 | 2 | 223,312 |
| Suramin | 2,604 | 6 | 15,624 | 7 | 109,368 |
| Pentamidine-suramin | 104 | 8 | 832 | 2 | 1,664 |
| 6 | 624 | 7 | 4,368 | ||
| Melarsoprol | 24,456 | 9 | 220,104 | 7 | 1,540,728 |
| Eflornithine | 377 | 14 | 5,278 | 22 | 116,116 |
| Nifurtimox§ | 1,168 | 100 | 116,800 | 0 | 0 |
| Melarsoprol-nifurtimox | 1,581 | 4 | 6,324 | 7 | 44,268 |
| 64 | 101,184 | 0 | 0 | ||
| Total | 44,247 | 2,039,824 |
*HAT, human African trypanosomiasis.
†Source of data: Programme National de Lutte contre la THA (PNLTHA) annual reports. The price of drugs is based on prices reported by the World Health Organization, 1998. Data for the HAT cases retreated in 2003 are not available.
‡Preferential price applicable during the period.
§PNLTHA did not buy nifurtimox in this period.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.